HomeCompareAMGN vs HII

AMGN vs HII: Dividend Comparison 2026

AMGN yields 2.77% · HII yields 1.48%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AMGN wins by $133.7K in total portfolio value
10 years
AMGN
AMGN
● Live price
2.77%
Share price
$349.00
Annual div
$9.66
5Y div CAGR
48.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$164.2K
Annual income
$69,743.86
Full AMGN calculator →
HII
HII
● Live price
1.48%
Share price
$369.08
Annual div
$5.46
5Y div CAGR
27.9%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.4K
Annual income
$2,464.27
Full HII calculator →

Portfolio growth — AMGN vs HII

📍 AMGN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAMGNHII
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AMGN + HII cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AMGN pays
HII pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AMGN
Annual income on $10K today (after 15% tax)
$235.27/yr
After 10yr DRIP, annual income (after tax)
$59,282.28/yr
HII
Annual income on $10K today (after 15% tax)
$125.75/yr
After 10yr DRIP, annual income (after tax)
$2,094.63/yr
At 15% tax rate, AMGN beats the other by $57,187.65/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AMGN + HII for your $10,000?

AMGN: 50%HII: 50%
100% HII50/50100% AMGN
Portfolio after 10yr
$97.3K
Annual income
$36,104.07/yr
Blended yield
37.11%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on AMGN right now

AMGN
Analyst Ratings
22
Buy
13
Hold
3
Sell
Consensus: Buy
Price Target
$347.73
-0.4% upside vs current
Range: $185.00 — $432.00
Altman Z
2.3
Piotroski
8/9
HII
Analyst Ratings
12
Buy
14
Hold
1
Sell
Consensus: Hold
Price Target
$368.00
-0.3% upside vs current
Range: $264.00 — $421.00
Altman Z
3.0
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AMGN buys
10
HII buys
2
PoliticianChamberTickerTypeAmountDate
David Taylor🏢 House$AMGN▼ Sell$1,001 - $15,0002026-02-26
David Taylor🏢 House$AMGN▼ Sell$1,001 - $15,0002026-01-29
David Taylor🏢 House$AMGN▲ Buy$1,001 - $15,0002026-01-16
David Taylor🏢 House$AMGN▼ Sell$1,001 - $15,0002025-12-03
David Taylor🏢 House$AMGN▼ Sell$1,001 - $15,0002025-12-03
Marjorie Taylor Greene🏢 House$AMGN▲ Buy$1,001 - $15,0002025-10-24
Lisa McClain🏢 House$AMGN▼ Sell$1,001 - $15,0002025-09-25
Marjorie Taylor Greene🏢 House$AMGN▲ Buy$1,001 - $15,0002025-09-11
Sheldon Whitehouse🏛 Senate$AMGN▼ Sell$1,001 - $15,0002025-09-04
Sheldon Whitehouse🏛 Senate$AMGN▼ Sell$1,001 - $15,0002025-09-04
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAMGNHII
Forward yield2.77%1.48%
Annual dividend / share$9.66$5.46
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR48.6%27.9%
Portfolio after 10y$164.2K$30.4K
Annual income after 10y$69,743.86$2,464.27
Total dividends collected$133.8K$9.0K
Payment frequencyquarterlyquarterly
SectorHealthcareIndustrials
Analyst consensusBuyHold
Analyst price target$347.73$368.00

Year-by-year: AMGN vs HII ($10,000, DRIP)

YearAMGN PortfolioAMGN Income/yrHII PortfolioHII Income/yrGap
1← crossover$11,111$411.31$10,889$189.21+$222.00AMGN
2$12,524$634.70$11,898$246.28+$626.00AMGN
3$14,394$993.52$13,052$321.65+$1.3KAMGN
4$16,987$1,585.83$14,388$421.78+$2.6KAMGN
5$20,776$2,599.19$15,951$555.75+$4.8KAMGN
6$26,645$4,414.70$17,804$736.46+$8.8KAMGN
7$36,373$7,863.06$20,032$982.58+$16.3KAMGN
8$53,826$14,907.12$22,756$1,321.55+$31.1KAMGN
9$88,231$30,636.84$26,144$1,794.47+$62.1KAMGN
10$164,151$69,743.86$30,438$2,464.27+$133.7KAMGN

AMGN vs HII: Complete Analysis 2026

AMGNHealthcare

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Full AMGN Calculator →

HIIIndustrials

Huntington Ingalls Industries, Inc. engages in designing, building, overhauling, and repairing military ships in the United States. It operates through three segments: Ingalls Shipbuilding, Newport News Shipbuilding, and Technical Solutions. The company is involved in the design and construction of non-nuclear ships comprising amphibious assault ships; expeditionary warfare ships; surface combatants; and national security cutters for the U.S. Navy and U.S. Coast Guard. It also provides nuclear-powered ships, such as aircraft carriers and submarines, as well as refueling and overhaul, and inactivation services of ships. In addition, the company offers naval nuclear support services, including fleet services comprising design, construction, maintenance, and disposal activities for in-service the U.S. Navy nuclear ships; and maintenance services on nuclear reactor prototypes. Further, it provides life-cycle sustainment services to the U.S. Navy fleet and other maritime customers; high-end information technology and mission-based solutions for Department of Defense (DoD), intelligence, and federal civilian customers; nuclear management and operations and environmental management services for the Department of Energy, DoD, state and local governments, and private sector companies; defense and federal solutions; and unmanned systems. Huntington Ingalls Industries, Inc. was founded in 1886 and is headquartered in Newport News, Virginia.

Full HII Calculator →
📬

Get this AMGN vs HII comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AMGN vs SCHDAMGN vs JEPIAMGN vs OAMGN vs KOAMGN vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.